Gastric Cancer Market Assessment, By Type [Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others], By Stages [Stage I, Stage II, Stage III, Stage IV, Others], By Drug Class [PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antag

Gastric Cancer Market Assessment, By Type [Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others], By Stages [Stage I, Stage II, Stage III, Stage IV, Others], By Drug Class [PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others], By Diagnosis [Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Others], By Treatment [Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Others], By Route of Administration [Oral, Parenteral, Others], By Distribution Channel [Hospital Pharmacy, Online Pharmacy, Retail Pharmacy], By End-users [Hospitals, Homecare,Specialty Centers, Others], By Region, Opportunities and Forecast, 2017-2031F



Global gastric cancer market size was valued at USD 4.87 billion in 2023, which is expected to reach USD 12.83 billion in 2031, growing with a CAGR of 12.88% for the forecast period between 2024 and 2031F. The global gastric cancer market pertains to a comprehensive landscape involving the diagnosis, treatment, and research dedicated to gastric (stomach) cancer. Gastric cancer is a significant health concern worldwide, it poses a considerable medical, economic, and social burden. The market encompasses a broad spectrum of activities, including innovative therapies, diagnostic tools, supportive care, and ongoing clinical research to address the challenges associated with the disease. Advancements in the gastric cancer market primarily focus on early detection techniques, personalized treatment options, and improving patient outcomes.

Diagnostic procedures involve endoscopic examinations, imaging technologies, and molecular diagnostic tests to identify the disease at its initial stages, significantly impacting treatment success rates. The market's landscape is continually evolving due to the emergence of novel therapeutic approaches and the integration of cutting-edge technologies. Clinical trials and research initiatives are ongoing, exploring innovative treatment options, including immunotherapies, precision medicines, and combination therapies. Collaboration between pharmaceutical companies, research institutions, and healthcare providers is critical for advancing the understanding of gastric cancer and developing more effective and targeted therapies. Additionally, initiatives aimed at raising awareness, early detection, and providing education about risk factors and symptoms play a crucial role in the overall management of gastric cancer on a global scale. The evolving landscape of gastric cancer market holds promise for improved patient outcomes, emphasizing the importance of continued research, innovation, and collaboration in the field.

New Innovations

The global gastric cancer market has seen significant advancements in recent years, driven by innovative technologies and treatment approaches. One notable innovation involves the emergence of precision medicine and targeted therapies tailored to individual patients based on specific molecular characteristics of their tumors. Immunotherapies, such as checkpoint inhibitors, have shown promise in some cases by enhancing the body's immune response against cancer cells. Additionally, advancements in minimally invasive surgical techniques, including robotic-assisted surgery, have improved treatment outcomes, reducing patient discomfort and recovery times.

Diagnostic tools too have evolved, with the development of liquid biopsies for early detection and monitoring of gastric cancer. These tests offer a less invasive method to analyze circulating tumor DNA, potentially allowing for quicker intervention and personalized treatment strategies. For instance, in January 2023, Eisai Co., Ltd. announced the showcasing of their research covering diverse gastrointestinal cancer types at the 2023 American Society of Clinical Oncology (ASCO) symposium on gastrointestinal cancers (#GI23), held in San Francisco, California.

Growing Regulatory Landscape

The Global Gastric Cancer Market product approvals are increasing due to the complex nature of these diseases. The increase in product approvals, collaboration, and innovation are pivotal. Research institutions, pharmaceutical companies, and regulatory bodies are collaborating closely to streamline clinical trials and expedite the approval process. Furthermore, investing in technological advancements like precision medicine and immunotherapy significantly enhances treatment outcomes, leading to more successful drug approvals.

For instance, in March 2023, Akeso, Inc., finalized the enrolment of patients for its crucial Phase III clinical trial for cadonilimab (AK104), a groundbreaking PD-1/CTLA-4 bi-specific antibody. The achievement represents a significant milestone as it is the first dual-immune checkpoint bi-specific antibody drug to receive approval and enter the market. The advancement brings cadonilimab one step closer to its official launch for a major indication following the successful approval for the treatment of cervical cancer.

Strategic Partnership Between Key Players

A strategic partnership between key players in global gastric cancer market holds significant promise for advancing the diagnosis, treatment, and overall management of the prevalent malignancy. Such collaborations can leverage the combined expertise and resources of pharmaceutical companies, research institutions, and healthcare providers to address the multifaceted challenges gastric cancer poses. These partnerships can accelerate the development of innovative therapies, diagnostic tools, and treatment protocols, ultimately improving patient outcomes. By pooling their knowledge and capabilities, stakeholders can better understand gastric cancer molecular underpinnings and optimize clinical trial designs, potentially leading to more effective and targeted treatments. Additionally, partnerships can facilitate early detection and screening programs, thereby increasing the chances of early intervention, and reducing the global burden of gastric cancer.

For instance, during February 2022, Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb entered a contract with Prime Research Institute for Medical RWD, Inc. This agreement aimed to conduct extensive, industry-sponsored, multi-institutional clinical research involving patients with gastric cancer. The study focused on the treatment involving Opdivo in conjunction with chemotherapy.

Development of Precision Medicine

Precision medicine in the global gastric cancer market has significantly advanced, leveraging individual patient variability in genes, environment, and lifestyle for tailored treatment. Innovations like next-generation sequencing, biomarker identification, and molecular profiling have revolutionized diagnosis and therapy selection. Targeted therapies, like trastuzumab for HER2-positive tumors, exemplify precision medicine's impact by improving patient outcomes. Companion diagnostics enables patients to respond to specific treatments, optimizing efficacy, and reducing adverse effects. The integration of big data analytics and artificial intelligence further refines treatment strategies, predicting responses and disease progression.

However, challenges such as cost, accessibility, and data interpretation persist, hindering widespread implementation. For instance, according to an article published in July 2022 in PubMed, the progress of precision medicine has continuously received substantial support from the remarkable strides achieved in both local and global studies concerning molecular targeted therapy for gastric cancer in recent years.

Impact of COVID-19

The global healthcare systems were widely impacted by the COVID-19 pandemic, significantly influencing the market for gastric cancer therapy. The diagnosis and treatment of gastric cancer experienced delays or cancellations owing to the worldwide lockdown measures. For example, a March 2023 article in PubMed highlighted how during the initial period of the pandemic, the care of gastric cancer patients worldwide suffered due to reduced multidisciplinary team meetings and a decline in elective gastrectomy. Amid the COVID-19 pandemic, delays in diagnosing and treating cancer placed patients at risk of negative consequences. These delays significantly affected the market's growth due to treatment and diagnosis disruptions. Nevertheless, the market for gastric cancer treatments has now reverted to its pre-pandemic state.

Key Players Landscape and Outlook

The competitive landscape of global gastric cancer market offers comprehensive insights on competitors. These details include company profiles, financial standings, revenue generation, market opportunities, research and development investments, new market strategies, international reach, manufacturing facilities, production capabilities, strengths and weaknesses, product launches, product diversity, and dominant applications. It is important to note that the mentioned data points specifically pertain to the companies' involvement in the global gastric cancer market.

BDR Pharma announced the introduction of Furmecil (recognized as S-1), a composite of three medications—Tegafur, Gimeracil, and Oteracil, in April 2022. Oral medication is specified for treating advanced gastric cancer in adults. According to a statement from BDR Pharma, Furmecil has displayed notable efficacy and a positive safety profile in its use.


1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on Global Gastric Cancer Market
4. Executive Summary
5. Global Gastric Cancer Market Outlook, 2017-2031F
5.1. Market Size & Forecast
5.1.1. By Value
5.1.2. By Volume
5.2. By Type
5.2.1. Adenocarcinoma
5.2.2. Lymphoma
5.2.3. Gastrointestinal Stromal Tumor
5.2.4. Carcinoid Tumor
5.2.5. Others
5.3. By Stages
5.3.1. Stage I
5.3.2. Stage II
5.3.3. Stage III
5.3.4. Stage IV
5.3.5. Others
5.4. By Drug Class
5.4.1. PD-1/PD-L1 Inhibitors
5.4.2. HER2 Antagonists
5.4.3. VEGFR2 Antagonists
5.4.4. Others
5.5. By Diagnosis
5.5.1. Endoscopy
5.5.2. Biopsy
5.5.3. Imaging Tests
5.5.4. Exploratory Surgery
5.5.5. Other
5.6. By Treatment
5.6.1. Surgery
5.6.2. Radiation Therapy
5.6.3. Chemotherapy
5.6.4. Targeted Therapy
5.6.5. Palliative Care
5.6.6. Others
5.7. By Route of Administration
5.7.1. Oral
5.7.2. Parenteral
5.7.3. Others
5.8. By Distribution Channel
5.8.1. Hospital Pharmacy
5.8.2. Online Pharmacy
5.8.3. Retail Pharmacy
5.9. By End-users
5.9.1. Hospitals
5.9.2. Homecare
5.9.3. Speciality Centres
5.9.4. Others
5.10. By Region
5.10.1. North America
5.10.2. Europe
5.10.3. Asia Pacific
5.10.4. South America
5.10.5. Middle East & Africa
5.11. By Company Market Share (%), 2023
6. Global Gastric Cancer Market Outlook, By Region, 2017-2031F
6.1. North America*
6.1.1. Market Size & Forecast
6.1.1.1. Value
6.1.1.2. Volume
6.1.2. By Type
6.1.2.1. Adenocarcinoma
6.1.2.2. Lymphoma
6.1.2.3. Gastrointestinal Stromal Tumor
6.1.2.4. Carcinoid Tumor
6.1.2.5. Others
6.1.3. By Stages
6.1.3.1. Stage I
6.1.3.2. Stage II
6.1.3.3. Stage III
6.1.3.4. Stage IV
6.1.3.5. Others
6.1.4. By Drug Class
6.1.4.1. PD-1/PD-L1 Inhibitors
6.1.4.2. HER2 Antagonists
6.1.4.3. VEGFR2 Antagonists
6.1.4.4. Others
6.1.5. By Diagnosis
6.1.5.1. Endoscopy
6.1.5.2. Biopsy
6.1.5.3. Imaging Tests
6.1.5.4. Exploratory Surgery
6.1.5.5. Other
6.1.6. By Treatment
6.1.6.1. Surgery
6.1.6.2. Radiation Therapy
6.1.6.3. Chemotherapy
6.1.6.4. Targeted Therapy
6.1.6.5. Palliative Care
6.1.6.6. Others
6.1.7. By Route of Administration
6.1.7.1. Oral
6.1.7.2. Parenteral
6.1.7.3. Others
6.1.8. By Distribution Channel
6.1.8.1. Hospital Pharmacy
6.1.8.2. Online Pharmacy
6.1.8.3. Retail Pharmacy
6.1.9. By End-users
6.1.9.1. Hospitals
6.1.9.2. Homecare
6.1.9.3. Speciality Centres
6.1.9.4. Others
6.1.10. United States*
6.1.10.1. Market Size & Forecast
6.1.10.1.1. Value
6.1.10.1.2. Volume
6.1.10.2. By Type
6.1.10.2.1. Adenocarcinoma
6.1.10.2.2. Lymphoma
6.1.10.2.3. Gastrointestinal Stromal Tumor
6.1.10.2.4. Carcinoid Tumor
6.1.10.2.5. Others
6.1.10.3. By Stages
6.1.10.3.1. Stage I
6.1.10.3.2. Stage II
6.1.10.3.3. Stage III
6.1.10.3.4. Stage IV
6.1.10.3.5. Others
6.1.10.4. By Drug Class
6.1.10.4.1. PD-1/PD-L1 Inhibitors
6.1.10.4.2. HER2 Antagonists
6.1.10.4.3. VEGFR2 Antagonists
6.1.10.4.4. Others
6.1.10.5. By Diagnosis
6.1.10.5.1. Endoscopy
6.1.10.5.2. Biopsy
6.1.10.5.3. Imaging Tests
6.1.10.5.4. Exploratory Surgery
6.1.10.5.5. Other
6.1.10.6. By Treatment
6.1.10.6.1. Surgery
6.1.10.6.2. Radiation Therapy
6.1.10.6.3. Chemotherapy
6.1.10.6.4. Targeted Therapy
6.1.10.6.5. Palliative Care
6.1.10.6.6. Others
6.1.10.7. By Route of Administration
6.1.10.7.1. Oral
6.1.10.7.2. Parenteral
6.1.10.7.3. Others
6.1.10.8. By Distribution Channel
6.1.10.8.1. Hospital Pharmacy
6.1.10.8.2. Online Pharmacy
6.1.10.8.3. Retail Pharmacy
6.1.10.9. By End-users
6.1.10.9.1. Hospitals
6.1.10.9.2. Homecare
6.1.10.9.3. Speciality Centres
6.1.10.9.4. Others
6.1.11. Canada
6.1.12. Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1. Germany
6.2.2. France
6.2.3. Italy
6.2.4. United Kingdom
6.2.5. Russia
6.2.6. Netherlands
6.2.7. Spain
6.2.8. Turkey
6.2.9. Poland
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.4. Asia-Pacific
6.4.1. India
6.4.2. China
6.4.3. Japan
6.4.4. Australia
6.4.5. Vietnam
6.4.6. South Korea
6.4.7. Indonesia
6.4.8. Philippines
6.5. Middle East & Africa
6.5.1. Saudi Arabia
6.5.2. UAE
6.5.3. South Africa
7. Market Mapping, 2023
7.1. By Type
7.2. By Stages
7.3. By Drug Class
7.4. By Diagnosis
7.5. By Treatment
7.6. By Route of Administration
7.7. By Distribution Channel
7.8. By End-users
7.9. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis – Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
8.4.1. Political Factors
8.4.2. Economic System
8.4.3. Social Implications
8.4.4. Technological Advancements
8.4.5. Environmental Impacts
8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter’s Five Forces Analysis
8.5.1. Supplier Power
8.5.2. Buyer Power
8.5.3. Substitution Threat
8.5.4. Threat from New Entrant
8.5.5. Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)
10. Regulatory Framework and Innovation
10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Novartis AG
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. F. Hoffmann-La Roche Ltd.
14.3. Bristol Myers Squibb Company
14.4. Eli Lilly and Company
14.5. Teva Pharmaceutical Industries Ltd.
14.6. Pfizer, Inc.
14.7. Mylan N.V.
14.8. Merck & Co., Inc.
14.9. Sanofi, Bayer AG
14.10. Johnson & Johnson Private Limited
14.11. Cipla Inc.
14.12. AbbVie Inc.
14.13. Sun Pharmaceutical Industries Ltd.
14.14. Aurobindo Pharma
14.15. Hikma Pharmaceuticals PLC
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings